ARTICLE | Product Development
Tempus aims for precision in complexity
With clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal
March 19, 2025 9:16 PM UTC
Tempus thinks it has the scale of data needed to deliver on the idea that the next era of precision medicine will go beyond single biomarkers to provide more holistic views of patients and their predicted responses to drugs.
Combining real-world data from about 9 million health records, >1.2 million patient images and DNA sequences, and over a quarter million patients with paired genomics and transcriptomics, Tempus AI Inc. (NASDAQ:TEM) is growing its portfolio of composite biomarkers that draw on more than one data modality...